Verrica Pharmaceuticals (VRCA) Other Working Capital Changes (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Other Working Capital Changes of $249000.0 for Q1 2026, up 427.63% year-over-year from $47192.0 in Q1 2025, and up 131.84% quarter-over-quarter from -$782000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Other Working Capital Changes (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Other Working Capital Changes history runs 8 years deep, the most recent figure standing at $249000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 427.63% year-over-year to $249000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 36800.0% YoY), while the FY2025 annual figure was $782000.0, changed N/A from the prior year.
- Other Working Capital Changes for Q1 2026 stood at $249000.0, up from -$782000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $2.1 million in Q3 2025, with the low at -$1.6 million in Q2 2023.
- The 5-year median for Other Working Capital Changes is -$371000.0 (2024), against an average of $48705.9.
- The sharpest annual moves came in 2022 and 2025: Other Working Capital Changes plunged 122.22% in 2022, then jumped 987.34% in 2025.
- Verrica Pharmaceuticals' Other Working Capital Changes stood at -$70000.0 in 2022, then gained by 4.29% to -$67000.0 in 2023, then jumped by 335.82% to $158000.0 in 2024, then slumped by 594.94% to -$782000.0 in 2025, then jumped by 131.84% to $249000.0 in 2026.
- Business Quant data shows VRCA's Other Working Capital Changes at $249000.0 in Q1 2026, -$782000.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Verrica Pharmaceuticals | 101.84 Mn | 90.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 251,000.00 |
| Jun 30, 2026 | 251,000.00 |
| Jun 30, 2026 | 251,000.00 |
| Mar 31, 2026 | -433,000.00 |
| Mar 31, 2026 | -433,000.00 |
| Mar 31, 2026 | -433,000.00 |
| Dec 31, 2025 | -1.01 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Sep 30, 2025 | 2.09 Mn |
| Sep 30, 2025 | 2.09 Mn |
| Sep 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | -272,000.00 |
| Jun 30, 2025 | -272,000.00 |
| Jun 30, 2025 | -272,000.00 |
| Mar 31, 2025 | -546,000.00 |
| Mar 31, 2025 | -546,000.00 |
| Mar 31, 2025 | -546,000.00 |
| Dec 31, 2024 | -371,000.00 |
| Dec 31, 2024 | -371,000.00 |